CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 28 enrolled
Drug / intervention
Sumatriptan Succinate +1 moredrug
Likely dose
Sumatriptan Succinate 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00847405
NCT00847405Phase 1Completed

A Two-Way Crossover, Open-Label, Single-Dose, Fasting Bioequivalence Study of Sumatriptan Succinate 100 mg Tablets Versus Imitrex® 100 mg Tablets in Normal Healthy Non-Smoking Male and Female Subjects

Teva Pharmaceuticals USA·interventional·Posted Feb 19, 2009·Updated Sep 11, 2009

In Brief

A Phase 1 clinical trial evaluating Sumatriptan Succinate and Imitrex® for Healthy. Completed, enrolled 28 participants across 1 site.

Detailed Summary

The objective of this study is to compare the rate and extent of absorption of sumatriptan from a test formulation of Sumatriptan Succinate 100 mg Tablets versus the reference Imitrex® 100 mg Tablets under fasting conditions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesCanada
Collaborators--

Timeline

Phase 1CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 19, 2009
Enrollment StartMar 1, 2003
Primary CompletionMar 1, 2003
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 17.4 years ago

Interventions

Sumatriptan Succinatedrug

100 mg Tablets

Imitrex®drug

100 mg Tablet